MYD88 GENE MUTATION

Clinical trials for MYD88 GENE MUTATION explained in plain language.

Never miss a new study

Get alerted when new MYD88 GENE MUTATION trials appear

Sign up with your email to follow new studies for MYD88 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo shows promise against rare blood cancer

Disease control Ongoing

This study tests whether combining two targeted drugs, ibrutinib and venetoclax, can shrink tumors in adults with Waldenström macroglobulinemia, a rare blood cancer. Participants must have a specific MYD88 gene mutation. The main goal is to see how many patients achieve a very go…

Matched conditions: MYD88 GENE MUTATION

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated May 19, 2026 11:59 UTC

MYD88 GENE MUTATION

Get alerted when new MYD88 GENE MUTATION trials appear

New drug combo shows promise against rare blood cancer